Biosimilar drugs are poised to transform the cancer drug market—so why is uptake so slow?
As more biosimilar agents are approved by the FDA, biologic manufacturers are looking for unique ways to hold on to market share.
While still largely a new phenomenon, biosimilars are here to stay—and this year will only bring more of them to market.
Biosimilar adoption is not happening as fast as once expected—will fears about future growth hold the market back?
The partial government shutdown is affecting the country in many ways—but how is it interfering with biosimilar development?
With a new ruling against the Affordable Care Act (ACA), many worry about the fate of the biosimilar market. But will it be as detrimental as feared?
2018 was meant to be a big year for the biosimilar market—but were developments as big as hoped? Find out.
In an effort to lower prescription drug prices, CMS unveiled proposed polices for 2020 to strengthen and modernize the Medicare Part C and D programs. Here’s a closer look at what CMS’ provisions entail and how they help accomplish the Administration’s four strategies.
With all eyes on drug prices, payers are looking to biosimilar agents to cut costs—and improve patient outcomes.
The biosimilar market is flourishing in Europe—why aren’t we seeing similar gains in the U.S.?